293 related articles for article (PubMed ID: 31559706)
21. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
Wang H; Barbieri CE; He J; Gao Y; Shi T; Wu C; Schepmoes AA; Fillmore TL; Chae SS; Huang D; Mosquera JM; Qian WJ; Smith RD; Srivastava S; Kagan J; Camp DG; Rodland KD; Rubin MA; Liu T
J Transl Med; 2017 Aug; 15(1):175. PubMed ID: 28810879
[TBL] [Abstract][Full Text] [Related]
22. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
[TBL] [Abstract][Full Text] [Related]
23. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
An J; Wang C; Deng Y; Yu L; Huang H
Cell Rep; 2014 Feb; 6(4):657-69. PubMed ID: 24508459
[TBL] [Abstract][Full Text] [Related]
24. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
[TBL] [Abstract][Full Text] [Related]
25. Snail promotes prostate cancer migration by facilitating SPOP ubiquitination and degradation.
Lv W; Huan M; Yang W; Gao Y; Wang K; Xu S; Zhang M; Ma J; Wang X; Chen Y; Li L
Biochem Biophys Res Commun; 2020 Aug; 529(3):799-804. PubMed ID: 32736710
[TBL] [Abstract][Full Text] [Related]
26. TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression.
Fong KW; Zhao JC; Song B; Zheng B; Yu J
Nat Commun; 2018 Nov; 9(1):5007. PubMed ID: 30479348
[TBL] [Abstract][Full Text] [Related]
27. LRP5 competes for SPOP binding to enhance tumorigenesis mediated by Daxx and PD-L1 in prostate cancer.
Gan S; Qu F; Zhang X; Pan X; Xu D; Cui X; Hou J
Exp Cell Res; 2024 Jan; 434(1):113857. PubMed ID: 38008278
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
Geng C; Rajapakshe K; Shah SS; Shou J; Eedunuri VK; Foley C; Fiskus W; Rajendran M; Chew SA; Zimmermann M; Bond R; He B; Coarfa C; Mitsiades N
Cancer Res; 2014 Oct; 74(19):5631-43. PubMed ID: 25274033
[TBL] [Abstract][Full Text] [Related]
29. Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
[TBL] [Abstract][Full Text] [Related]
30. Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
García-Flores M; Casanova-Salas I; Rubio-Briones J; Calatrava A; Domínguez-Escrig J; Rubio L; Ramírez-Backhaus M; Fernández-Serra A; García-Casado Z; López-Guerrero JA
Eur J Cancer; 2014 Nov; 50(17):2994-3002. PubMed ID: 25204806
[TBL] [Abstract][Full Text] [Related]
31. Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers.
Kim MS; Je EM; Oh JE; Yoo NJ; Lee SH
APMIS; 2013 Jul; 121(7):626-33. PubMed ID: 23216165
[TBL] [Abstract][Full Text] [Related]
32. Deregulation of SPOP in Cancer.
Zhang H; Jin X; Huang H
Cancer Res; 2023 Feb; 83(4):489-499. PubMed ID: 36512624
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.
Jin X; Qing S; Li Q; Zhuang H; Shen L; Li J; Qi H; Lin T; Lin Z; Wang J; Cao X; Yang J; Ma Q; Cong L; Xi Y; Fang S; Meng X; Gong Z; Ye M; Wang S; Wang C; Gao K
Nucleic Acids Res; 2021 Jul; 49(12):6788-6803. PubMed ID: 34133717
[TBL] [Abstract][Full Text] [Related]
34. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
Shoag J; Liu D; Blattner M; Sboner A; Park K; Deonarine L; Robinson BD; Mosquera JM; Chen Y; Rubin MA; Barbieri CE
J Clin Invest; 2018 Jan; 128(1):381-386. PubMed ID: 29202479
[TBL] [Abstract][Full Text] [Related]
35. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.
Theurillat JP; Udeshi ND; Errington WJ; Svinkina T; Baca SC; Pop M; Wild PJ; Blattner M; Groner AC; Rubin MA; Moch H; Prive GG; Carr SA; Garraway LA
Science; 2014 Oct; 346(6205):85-89. PubMed ID: 25278611
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
[TBL] [Abstract][Full Text] [Related]
38. Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
Gang X; Xuan L; Zhao X; Lv Y; Li F; Wang Y; Wang G
Prostate; 2019 Jun; 79(8):864-871. PubMed ID: 30955223
[TBL] [Abstract][Full Text] [Related]
39. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
Ma J; Chang K; Peng J; Shi Q; Gan H; Gao K; Feng K; Xu F; Zhang H; Dai B; Zhu Y; Shi G; Shen Y; Zhu Y; Qin X; Li Y; Zhang P; Ye D; Wang C
J Exp Clin Cancer Res; 2018 Jul; 37(1):145. PubMed ID: 29996942
[TBL] [Abstract][Full Text] [Related]
40. Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.
Ji D; Shang G; Wei E; Jia Y; Wang C; Zhang Q; Zeng L
Oncogene; 2022 Jun; 41(23):3251-3262. PubMed ID: 35513563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]